Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme – results from the non-interventional post-authorization safety study PRIMA

Autor: Juliane Klehmet, Yvonne Begus-Nahrmann, Kirsi Taipale, Gabriele Niemczyk, Karin Rehberg-Weber

Publikováno v: Therapeutic Advances in Neurological Disorders, Vol 16 (2023)

Background: Based on data from two large cohort studies, a label update became applicable for the class of interferon beta therapies in 9/2019, allowing interferons during pregnancy and breastfeeding. Objective: To assess pregnancy outcomes of women

Externí odkaz: https://doaj.org/article/51383f3942344e15b2872c75be847132

Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients – Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting – Results from the Non-Interventional Study PERFECT

Autor: Andreas Kowalik, Patrick Oschmann, Borries Kukowski, Kirsi Taipale, Karin Rehberg-Weber

Publikováno v: Patient preference and adherence

Borries Kukowski,1 Karin Rehberg-Weber,2 Kirsi Taipale,2 Andreas Kowalik,3 Patrick Oschmann4 1Neurologische Gemeinschaftspraxis, Göttingen, Germany; 2Biogen GmbH, Munich, Germany; 3Praxis Dr. Kowalik, Stuttgart, Germany; 4Klinik für Neurologie, Kli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::257f9f294380d781065b96cd2d6d0c4a
https://www.dovepress.com/subcutaneous-interferon-beta-therapy-in-multiple-sclerosis-patients--c-peer-reviewed-fulltext-article-PPA

Interferon Beta-1a (AVONEX®) as a treatment option for untreated patients with multiple sclerosis (AXIOM): a prospective, observational study

Autor: Karin Rehberg-Weber, Colin Wernsdörfer, Gabriele Niemczyk, Christoph Kleinschnitz

Publikováno v: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 16, Iss 7, Pp 15271-15286 (2015)
Volume 16
Issue 7
Pages 15271-15286

The efficacy and safety of first-line disease-modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in pivotal, randomized trials, but these studies do not reflect the routine care setting where treatment g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0badc05454bb86cfe67e95b6eaf6d1c
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-148487